Table 3.
Lipid mediator profiles from nasal secretions.
| Control (pg/mg protein) | CRSwNP (pg/mg protein) | URTI (pg/mg protein) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| DHA metabolome | mean | ± | sem | mean | ± | sem | mean | ± | sem |
| RvD1 | – | – | 0.03 | ± | 0.03 | ||||
| 17R-RvD1 | – | – | – | ||||||
| RvD2 | – | – | – | ||||||
| RvD3 | – | – | 1.86 | ± | 1.56 | ||||
| 17R-RvD3 | – | 0.42 | ± | 0.23 | – | ||||
| RvD4 | – | – | – | ||||||
| RvD5 | 103.06 | ± | 85.45 | 398.47 | ± | 143.36 | 975.15 | ± | 493.43 |
| RvD6 | – | – | – | ||||||
| PD1 | – | 10.71 | ± | 3.41 | 1.62 | ± | 0.93 | ||
| 10S,17S-diHDAH | 9.41 | ± | 8.59 | 25.30 | ± | 25.70 | 56.49 | ± | 40.33 |
| 22-OH-PD1 | – | – | – | ||||||
| 17R-PD1 | – | 0.91 | ± | 0.70 | – | ||||
| MaR1 | – | 788.95 | ± | 559.54 | 26.22 | ± | 25.47 | ||
| 7S,14S-diHDHA | – | 26.74 | ± | 11.86 | 1.57 | ± | 1.19 | ||
| MaR2 | – | 16.13 | ± | 12.97 | 0.62 | ± | 0.46 | ||
| 22-OH-MaR1 | – | – | – | ||||||
| 22-COOH-MaR1 | – | – | – | ||||||
| 14-oxo-MaR1 | – | – | – | ||||||
| 4,14-diHDHA | – | 0.33 | ± | 0.34 | – | ||||
| n-3 DPA metabolome | |||||||||
| RvT1 | – | – | 0.37 | ± | 0.32 | ||||
| RvT2 | – | – | – | ||||||
| RvT3 | – | – | – | ||||||
| RvT4 | – | – | – | ||||||
| RvD1n-3 DPA | – | 0.02 | ± | 0.01 | – | ||||
| RvD2n-3 DPA | – | 0.04 | ± | 0.04 | – | ||||
| RvD5n-3 DPA | – | 21.26 | ± | 10.23 | 0.93 | ± | 0.65 | ||
| PD1 n-3 DPA | 4.98 | ± | 4.54 | – | – | ||||
| PD2 n-3 DPA | 44.61 | ± | 40.72 | – | 29.21 | ± | 23.99 | ||
| 10S, 17S-diHDPA | – | 0.06 | ± | 0.06 | 0.10 | ± | 0.11 | ||
| 22-OH-PD1n n-3 DPA | – | – | – | ||||||
| MaR1n-3 DPA | – | – | – | ||||||
| MaR2n-3 DPA | – | – | – | ||||||
| 7S,14S-diHDPA | – | – | – | ||||||
| AA metabolome | |||||||||
| RvE1 | – | – | – | ||||||
| RvE2 | – | – | – | ||||||
| RvE3 | 104.09 | ± | 95.02 | 78.40 | ± | 79.65 | 48.23 | ± | 29.01 |
| AA metabolome | |||||||||
| LXA4 | – | 3.22 | ± | 2.00 | 149.68 | ± | 154.44 | ||
| LXB4 | – | 32.75 | ± | 15.98 | 37.82 | ± | 13.93 | ||
| 5S,15S-diHETE | 146.84 | ± | 134.05 | 96.91 | ± | 98.46 | 135.93 | ± | 84.12 |
| 13,14-dehydro-15-oxo-LXA4 | – | – | – | ||||||
| 15-oxo-LXA4 | – | 1.57 | ± | 0.88 | 0.04 | ± | 0.03 | ||
| 15-epi-LXA4 | – | 2.46 | ± | 1.97 | |||||
| 15-epi-LXB4 | 263.41 | ± | 240.46 | 0.15 | ± | 0.16 | 0.00 | ± | 0.00 |
| LTB4 | 71.93 | ± | 42.07 | 161.59 | ± | 56.43 | 157.18 | ± | 80.03 |
| 5S,12S-diHETE | – | 0.32 | ± | 0.32 | – | ||||
| 6-trans-LTB4 | 38.19 | ± | 33.42 | 85.22 | ± | 39.31 | 124.85 | ± | 60.29 |
| 6-trans-12-epi-LTB4 | – | 94.39 | ± | 44.69 | 52.73 | ± | 49.82 | ||
| 20-OH-LTB4 | – | 501.80 | ± | 373.60 | 26.16 | ± | 21.46 | ||
| 20-COOH-LTB4 | – | 10.17 | ± | 4.71 | 13.50 | ± | 6.26 | ||
| PGE2 | 1926.04 | ± | 1110.20 | 265.65 | ± | 54.78 | 1408.65 | ± | 411.74 |
| PGD2 | 1.81 | ± | 1.65 | 37.97 | ± | 19.05 | 489.73 | ± | 236.24 |
| PGF2a | 718.47 | ± | 501.80 | 96.36 | ± | 18.92 | 434.53 | ± | 148.98 |
| TxB2 | 7.69 | ± | 4.45 | 5.96 | ± | 4.75 | 3.18 | ± | 1.46 |
| LTC4 | – | – | – | ||||||
| LTD4 | – | – | – | ||||||
| LTE4 | – | 9.73 | ± | 2.95 | 2.55 | ± | 1.45 | ||
Plasma was collected from patients with CRSwNP (n = 16) healthy volunteers (n = 5) and subjects with URTI (8) and LM were extracted using C18 SPE and LM concentrations determined using LC-MS/MS based LM profiling. - = Below limits.